Comparative Pharmacology
Head-to-head clinical analysis: VASOCON A versus VISINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: VASOCON A versus VISINE.
VASOCON-A vs VISINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Antazoline is an H1-receptor antagonist that blocks histamine-induced vasodilation and increased capillary permeability. Naphazoline is a direct-acting alpha-adrenergic agonist that constricts conjunctival blood vessels, reducing redness and swelling.
Tetrahydrozoline is a sympathomimetic amine that acts as an alpha-1 adrenergic receptor agonist, causing vasoconstriction of conjunctival blood vessels, thereby reducing redness and edema.
Adults: 1-2 drops in each nostril every 8-12 hours, not to exceed 2 doses per day. Do not use for more than 3 consecutive days.
1-2 drops in affected eye(s) every 6-8 hours as needed, not to exceed 4 times daily.
None Documented
None Documented
Terminal elimination half-life: 6-8 hours; extends to 12-18 hours in hepatic impairment.
Approximately 1-2 hours for ocular absorption; systemic half-life not clinically relevant due to low systemic absorption
Renal excretion of unchanged drug: 60-80%; biliary/fecal: 20-40% as metabolites.
Primarily renal as unchanged drug and metabolites; minor biliary/fecal elimination (<10%)
Category C
Category C
Ophthalmic Decongestant/Antihistamine Combination
Ophthalmic Decongestant